{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T23:59:17Z","timestamp":1773878357152,"version":"3.50.1"},"reference-count":15,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":303,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Breast Cancer"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:p>Patients with advanced HR+\/HER2\u2212 breast cancer often experience prolonged disease courses, with bone being a dominant site of metastasis. Bone\u2010targeted agents (BTAs) are recommended to reduce the risk of skeletal\u2010related events (SREs), yet most clinical trials report follow\u2010up durations of less than 2 years. Here, we present two cases of patients with breast cancer and bone metastases who received continuous BTA therapy for 8 and 10 years, respectively, in the context of ongoing antitumor treatment. Neither patient developed SREs during follow\u2010up. The two cases demonstrated good tolerabilit during long\u2010term treatment, though broader conclusions regarding safety require further investigation.<\/jats:p>","DOI":"10.1155\/ijbc\/9601887","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T04:34:16Z","timestamp":1761971656000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Long\u2010Term Management of Breast Cancer Bone Metastases: Two Case Reports"],"prefix":"10.1155","volume":"2025","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8994-9735","authenticated-orcid":false,"given":"Xiaoting","family":"Lin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-2380-3254","authenticated-orcid":false,"given":"Ru","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"e_1_2_9_1_2","doi-asserted-by":"publisher","DOI":"10.21037\/tbcr-20-65"},{"key":"e_1_2_9_2_2","doi-asserted-by":"publisher","DOI":"10.1111\/jebm.12571"},{"key":"e_1_2_9_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2114663"},{"key":"e_1_2_9_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00137"},{"key":"e_1_2_9_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199612123352401"},{"key":"e_1_2_9_6_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.7101"},{"key":"e_1_2_9_7_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2018.1532884"},{"key":"e_1_2_9_8_2","first-page":"377","article-title":"Zoledronic Acid Versus Pamidronate in the Treatment of Skeletal Metastases in Patients With Breast Cancer or Osteolytic Lesions of Multiple Myeloma: A Phase III, Double-Blind, Comparative Trial","volume":"7","author":"Rosen L. S.","year":"2001","journal-title":"Cancer Journal"},{"key":"e_1_2_9_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.07.019"},{"key":"e_1_2_9_10_2","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2012.689254"},{"key":"e_1_2_9_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/pcan.2017.4"},{"key":"e_1_2_9_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-019-04676-6"},{"key":"e_1_2_9_13_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdr435"},{"key":"e_1_2_9_14_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-015-2904-5"},{"key":"e_1_2_9_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn526"}],"container-title":["International Journal of Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijbc\/9601887","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1155\/ijbc\/9601887","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/ijbc\/9601887","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T10:01:41Z","timestamp":1772964101000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/ijbc\/9601887"}},"subtitle":[],"editor":[{"given":"Sreeja","family":"Dattachoudhury","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1155\/ijbc\/9601887"],"URL":"https:\/\/doi.org\/10.1155\/ijbc\/9601887","archive":["Portico"],"relation":{},"ISSN":["2090-3170","2090-3189"],"issn-type":[{"value":"2090-3170","type":"print"},{"value":"2090-3189","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-10","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-31","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"9601887"}}